Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC

TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and deregister its common stock with the Securities and Exchange Commission (the “SEC”).

The Company is in compliance with applicable Nasdaq listing requirements, but the Company’s Board of Directors has concluded the resources required to continue its reporting obligations with the SEC are greater than the benefits received by the Company and its shareholders on account of the Nasdaq listing.

The Company has notified Nasdaq of its intent to voluntarily delist and deregister its common stock. The Company intends to file a Form 25 (Notification of Removal from Listing) with the SEC on or about January 30, 2026 and expects the last trading day of the Company’s common stock on Nasdaq will be on or about February 6, 2026. The Company also intends to file a Form 15 (Certification and Notice of Termination From Registration) with the SEC on or about February 9, 2026, upon which the Company's obligation to file periodic reports with the SEC, including Forms 10-K, 10-Q and 8-K, will be immediately suspended.

"The Board of Directors, after thorough evaluation, has determined this action is in the best interests of the Company and its shareholders. We believe the reduced costs for compliance will help facilitate the Company's ability to continue to execute our turnaround plan," said Rajiv De Silva, Chief Executive Officer of Venus Concept. "Venus will continue to work together with Madryn Asset Management to position Venus for sustained, long-term financial success."

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, Masters Special Situations, and Madryn Asset Management, L.P.